Pilot study suggests injectable BOAS therapy may widen options

Version 1 — Brief

A pilot study published in The Veterinary Journal reports early promise for Snoretox-1, an investigational injectable therapy for brachycephalic obstructive airway syndrome, or BOAS, in British bulldogs. In the six-dog study, all dogs improved by at least one Respiratory Function Grading level after treatment, with reported benefit lasting 20 to 53 weeks. The therapy, developed by Melbourne-based Snoretox in collaboration with RMIT University, is designed to increase upper-airway muscle tone using a modified tetanus-toxin-based approach, with the goal of improving airflow in dogs that would otherwise be managed with surgery, weight control, or both. (rmit.edu.au)

Why it matters: For veterinary professionals, the finding is notable because BOAS remains a multilevel, chronic airway disorder with variable surgical outcomes and meaningful anesthetic and postoperative risk. Current management often includes rhinoplasty, staphylectomy, and other airway procedures, but dogs may continue to have residual signs after surgery, and perioperative respiratory complications remain a concern. If larger studies confirm safety, durability, and reproducible benefit, Snoretox-1 could emerge as an adjunct to surgery, or a less invasive option for selected cases, including dogs that have not responded adequately to prior procedures. (dvm360.com)

What to watch: The next key milestone is a larger-scale trial, which the RMIT-Snoretox team says is being planned. (rmit.edu.au)